Apogee Technology, Inc. (ATA) Reports Completion of In Vivo Proof-of-Concept Studies and Filing of U.S. Patent Application  
4/30/2008 10:25:06 AM

NORWOOD, MA--(Marketwire - April 30, 2008) - Apogee Technology, Inc. (OTCBB: ATCS) (the "Company"), which is developing PyraDermâ„¢, a proprietary intradermal drug delivery system for vaccines and other pharmaceuticals, and IntellaPALâ„¢, a proprietary sensor based health monitoring system for the elderly care market, today reported the completion of in vivo proof-of-concept studies and the filing of a new U.S. patent application relating to its intradermal drug delivery technology. The patent application encompasses formulations and compounds that can be instrumental in the development of efficient intradermal vaccines.